# 1. Financial Performance ## A. Key Figures * **Standalone Revenue:** **Rs. 2,279 Cr** Q4 (+16.5% YoY) · **Rs. 8,556 Cr** FY26 (+8.4% YoY) * **PBT (Pre-Exceptional):** **Rs. 361 Cr** Q4 (+10.4% YoY) · **Rs. 1,099 Cr** FY26 (+12.7% YoY) * **TII Consolidated Revenue:** **Rs. 6,215 Cr** Q4 · **Rs. 22,847 Cr** FY26 * **TII Consolidated Profit:** **Rs. 516 Cr** Q4 · **Rs. 1,937 Cr** FY26 * **Free Cash Flow:** **Rs. 313 Cr** Q4 · **Rs. 826 Cr** FY26 (100% of PAT) * **ROIC:** **44%** FY26 (Flat YoY) ## B. Revenue & Profit * **Steady Growth Profile:** Achieved high single-digit annual revenue growth and double-digit PBT expansion, reflecting resilient standalone operations. * **Consolidated Strength:** TII group performance remains robust, contributing significant scale to the overall consolidated top-line and profitability. ## C. Margin & ROIC * **Capital Efficiency:** Maintained industry-leading ROIC levels, demonstrating consistent discipline in capital deployment and operational execution. * **Cost Mitigation:** Actively neutralizing fuel and input cost inflation through internal efficiencies and customer price negotiations. * **Strategic Sourcing:** Prioritizing BOM cost reductions and **increased localization** across all four business platforms to protect long-term margins. ## D. Cash Flow & Capital Allocation * **Cash Conversion:** Exceptional cash generation with annual free cash flow matching total net profit, highlighting high-quality earnings. * **Shareholder Returns:** Total dividend payout for the fiscal year reached **Rs. 3.50 per share**, supported by strong liquidity and cash flow. --- # 2. Segment & Subsidiary Performance ## A. Key Figures * **Engineering Revenue:** **₹1,495 Cr** Q4 · **₹5,612 Cr** FY * **Engineering PBIT:** **₹176 Cr** Q4 · **₹689 Cr** FY * **Metal Formed Products (MFP) Revenue:** **₹421 Cr** Q4 · **₹1,603 Cr** FY * **MFP PBIT:** **₹35 Cr** Q4 · **₹162 Cr** FY * **Mobility Revenue:** **₹208 Cr** Q4 (+15%) · **₹783 Cr** FY * **Mobility PBIT:** **₹4 Cr** Q4 · **₹19 Cr** FY (+280%) * **CG Power (56% Stake) Revenue:** **₹3,442 Cr** Q4 · **₹12,418 Cr** FY * **CG Power (56% Stake) Profit:** **₹490 Cr** Q4 · **₹1,662 Cr** FY * **Shanthi Gears (70% Stake) Revenue:** **₹135 Cr** Q4 · **₹519 Cr** FY ## B. Engineering & Metal Formed Products * **Engineering Volume Momentum:** Segment growth was driven entirely by volume expansion, as pricing remained neutral during the final quarter. * **MFP Structural Headwinds:** Performance remains sluggish due to lower profitability in **railway tenders** and delayed development cycles with private sector partners. * **Hyundai Dependency:** MFP results were pressured by a major customer's performance, though management expects a recovery as **Hyundai** ramps up new production in Western India. ## C. Mobility & Other Businesses * **Mobility Turnaround:** The segment demonstrated significant bottom-line scaling, with full-year PBIT nearly quadrupling on steady revenue growth. * **Diversified Growth:** "Other" business units showed consistent improvement, contributing **₹70 Cr** in full-year PBIT, up from **₹48 Cr** in the prior year. ## D. Subsidiaries * **CG Power Dominance:** The subsidiary remains a massive contributor to the consolidated profile, delivering over **₹12,400 Cr** in annual revenue. * **Shanthi Gears Contraction:** The unit faced a quarterly decline in both top and bottom-line performance, ending the year with a profit of **₹107 Cr**. --- # 3. EV & Clean Mobility ## A. Key Figures * **Market Share:** **28%** Electric Trucks (FY Lead) · **27%** SCV (Q4) * **Q4 Sales Volume:** **87 units** M&HCV · **241 units** SCV · **1,176 units** 3W · **0 units** Tractors ## B. Market Leadership & Positioning * **Dominant Market Share:** Secured the top position in the electric truck segment and a significant portion of the SCV market despite facing intense competition from **11** and **7** players respectively. * **Regulatory Milestone:** The Montra Electric Rhino achieved a first-mover advantage as the initial electric truck certified under the **PM E-drive scheme**, facilitating government-backed purchase incentives. ## C. Charging & Battery Technology * **Infrastructure Pivot:** Management is prioritizing high battery capacity and fast charging for long-haul transport over swapping technology, citing the prohibitive setup costs of swapping infrastructure. * **Battery Chemistry Outlook:** Sodium-ion technology is viewed as a long-term prospect rather than a near-term catalyst, with no immediate impact on TCO expected due to extensive validation and implementation timelines. ## D. Strategic Initiatives & Operations * **Localization Drive:** Aggressive cost reduction and component localization are underway across all **four EV platforms** to facilitate scaling, though geopolitical tensions remain a headwind. * **Segment Performance:** Robust volume traction in three-wheelers and commercial vehicles contrasts with a stagnant tractor segment, which recorded no billings during the quarter. --- # 4. Manufacturing & Capacity ## A. Key Figures * **CRSS Plant Utilization (Nasik):** **100%** Projected target (End FY / Mid-Next FY) * **Western Tube Utilization:** **30%** Current · **100%** Target (Mid-Next FY) * **Production Scale Targets:** **1,000 to 2,000+** Units (Body-in-white/Three-wheeler) ## B. Facility Utilization & Ramp-up * **Strategic Capacity Expansion:** Robust utilization targets for the Nasik and Western tube facilities signal a transition from ramp-up to full-scale operational efficiency by next year. * **Stabilizing Pune Operations:** The Pune facility is currently scaling to meet **Hyundai’s door frame requirements**, with management expecting stabilization this quarter following minor teething issues. * **Three-Wheeler Recovery:** Normal production capacity is expected by **end-Q1**, bolstered by strong market reception for the upgraded Super Auto version. ## C. Asset Acquisitions & Supply Chain * **Vertical Integration Strategy:** Acquisition of a struggling body-in-white supplier near the three-wheeler unit has resolved critical supply chain bottlenecks and met production targets for **April and May**. * **Medical Segment Entry:** The Ambala facility purchase for the IV cannula business is progressing toward **Q2 commercial production**, with approvals and hiring slated for **Q1**. --- # 5. Product & Pipeline Progress ## A. Medical Device Expansion * **Export Scaling:** Successfully expanding the medical device footprint across **Europe and Southeast Asian** markets despite regional volatility. * **Macro Sensitivity:** Sustained business momentum remains contingent on broader macroeconomic conditions and regional stability. ## B. Railway & Vande Bharat * **Development Milestone:** Product development for **Vande Bharat** coach components is finalized, shifting the focus to commercial execution. * **Regulatory Timeline:** Commercialization is currently stalled pending **Government of India approval**, with a projected breakthrough in **two to three quarters**. ## C. CDMO Business Scaling * **Facility Readiness:** The **Naidupet CDMO manufacturing plant** has reached the final commissioning phase. * **Production Launch:** Commercial operations are slated to commence in the **upcoming quarter**, marking a key transition to revenue generation for the segment. ## D. Product Development Cycles * **Competitive Moat:** Market positioning is anchored by a **solution-selling approach** and high product reliability rather than commoditized offerings. --- # 6. Risks & Macro Factors ## A. Key Figures * **Capital Requirement:** **>₹100 Cr** for heavy truck fleet deployments (50-100 units) * **Price Recovery Lag:** **1 to 2 quarters** for commodity cost pass-through ## B. Operational & Geopolitical Headwinds * **Supply Chain Disruption:** A critical body-in-white supplier issue severely constrained three-wheeler production, leading to significant underutilization and impacted retail volumes. * **Export Barriers:** Despite achieving necessary regulatory certifications, medical device exports face growth resistance due to Middle East instability and broader geopolitical conflicts. ## C. Strategic & Macro Challenges * **Infrastructure & Financing Hurdles:** Scaling heavy electric trucks is hampered by high capital intensity for fleet operators and the logistical difficulty of establishing route-specific charging networks. * **Inflation Management:** Commodity price volatility is mitigated through contractual recovery mechanisms, though margins remain exposed to short-term timing lags. --- # 7. Guidance & Outlook ## A. Key Figures * **Growth Targets:** **15% to 20%** Wound Care (Suture) · **20%** TI Medical * **Planned Capex:** **₹300 Cr to ₹350 Cr** Standalone Core Business ## B. Growth Target Projections * **Bullish Sector Outlook:** Management anticipates robust double-digit expansion across specialized medical verticals, signaling high confidence in the healthcare portfolio. ## C. Capex & Investment Plan * **Strategic Capital Allocation:** Significant investment earmarked for scaling EV operations and medical subsidiaries alongside core business maintenance. * **Capacity Expansion:** Evaluation of the **CRSS plant** expansion is underway, with a final investment decision slated for a **six-month** horizon. ## D. Demand & Order Book * **Resilient Volume Momentum:** Strong demand persists into the early part of **Q1 FY2027**, effectively navigating macroeconomic headwinds and inflationary fuel pressures. * **EV Segment Upswing:** Robust order book visibility for heavy trucks driven by a cyclical demand surge in the HCV and SCV categories. ## E. Operational Stabilization Targets * **Deployment Timeline:** Commercial rollout of heavy trucks is scheduled for **H1 FY2027**, contingent on clearing existing financing and infrastructure bottlenecks.